我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
9
2 进行中
药物批准
0
批准总数
监管机构
监管机构数
成立时间
1973
尚未招募
2
22.2%
招募中
7
77.8%
暂无批准数据
- The phase 3 BM12 CAST trial demonstrated that cyclophosphamide plus cyclosporin significantly improved graft-versus-host disease-free relapse-free survival compared to standard cyclosporin/methotrexate prophylaxis in blood cancer patients. - Median GVHD-free relapse-free survival reached 26.2 months with the new combination versus 6.4 months with standard therapy, representing a 58% reduction in risk. - At three years, 49.1% of patients receiving cyclophosphamide/cyclosporin remained free from GVHD compared to only 14.2% with standard treatment. - The study enrolled 134 patients with acute leukemia or myelodysplastic syndrome across 10 transplant centers in Australia and New Zealand.
